Dr. Viktor Grünwald on Dovitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma

Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with metastatic renal cell carcinoma (mRCC) following prior treatment with one VEGF inhibitor and one mTOR inhibitor. For more from the European Cancer Congress, visit http://www.onclive.com/conference-cov...